One drug, nivolumab, which disarms the immune system, extended survival by almost six months, compared with standard treatment, the research in the New England Journal of Medicine found. A second drug cabozantinib - which blocks enzymes which drive tumour growth, was found to slow disease progression by twice as long as standard treatment.